Clinical trials: AML With Gene Mutations
Acute Myeloid Leukemia, TP53 Gene Mutation
Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML
Axatilimab combined with Decitabine/Venetoclax for the treatment of TP53-mutated/deleted AML patients
- Trial name
- NCT07511062
- Testing
- Decitabine, Venetoclax, Axatilimab
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Northside Hospital, Inc.
Acute Myeloid Leukemia With FLT3 Activating Mutations That Has Relapsed or Been Refractory After One or More Prior Therapies
A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations
This pilot Phase II study is designed to evaluate the efficacy and tolerability of crenolanib in two cohorts of AML patients with FLT3 activation mutations (patients whose leukemia has recurred after prior chemotherapy not…
- Trial name
- NCT01657682
- Testing
- Crenolanib besylate
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Arog Pharmaceuticals, Inc.
Leukemia
Biomarkers in Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01138319
- Testing
- DNA analysis, mutation analysis, polymerase chain reaction
- Volunteers
- 18 people
- Sponsor
- Children's Oncology Group
Acute Myeloid Leukemia (AML), FMS-like Tyrosine Kinase-3 (FLT3) Mutations
Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
The purpose of this study is to provide expanded access to ASP2215 for subjects with FLT3-mutated relapsed or refractory AML or FLT3-mutated AML in composite complete remission (CRc) (complete remission [CR], complete remission…
- Trial name
- NCT03070093
- Testing
- gilteritinib
- Where
- 39 sites in United States, Canada and 1 more
- Sponsor
- Astellas Pharma Global Development, Inc.
Leukemia
Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia
RATIONALE: Studying bone marrow samples from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01247584
- Testing
- DNA analysis, mutation analysis, polymerase chain reaction
- Volunteers
- 234 people
- Sponsor
- Children's Oncology Group
Acute Myeloid Leukemia, P53 Mutation
Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations
This is a prospective,uncontrolled and multi-institution trial.The aim is to identify if using decitabine,cytarabine and ATO as the therapy of acute myeloid leukemia(AML) with p53 mutations has better relapse free survival and…
- Trial name
- NCT03381781
- Testing
- Decitabine, Arsenic Trioxide, Cytarabine
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Li Junmin
Leukemia, Myeloid
Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation
The purpose of this study is to determine the response rate of patients with refractory, relapsed or poor risk AML expressing FLT-3 activating mutations, when administered CEP-701 at a dosage of 60 mg 2 times a day.
- Trial name
- NCT00030186
- Testing
- CEP-701 60mg, Cep-701 80mg, Cep-701 40mg
- Volunteers
- 37 people
- Sponsor
- Cephalon
FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive
Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
This phase I/II trial studies the side effects and best dose of quizartinib when given in combination with azacitidine or cytarabine in treating patients with acute myeloid leukemia or myelodysplastic syndrome that have come back…
- Conditions
- FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia
- Trial name
- NCT01892371
- Testing
- Azacitidine, Cytarabine, Quizartinib
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- M.D. Anderson Cancer Center
Core Binding Factor Acute Myeloid Leukemia, KIT Mutation-Related Tumors
Avapritinib in CBF-AML With KIT Mutations
AML with t(8; 21)(q22; q22) or inv(16)(p13; q22)/t(16; 16)(p13; q22) is known as CBF-AML. KIT mutations are common in CBF-AML, which have a worse prognosis.This study is aimed to evaluate the efficacy of Avapritinib, an highly…
- Trial name
- NCT05821738
- Testing
- Avapritinib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Soochow University
AML - Acute Myeloid Leukemia
Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment
Explore the best tolerable and efficacious dose of Gilteritinib when combined with standard treatment with Venetoclax and Azacitidine in AML patients with FLT3 mutations which are ineligible for intensive chemotherapy
- Trial name
- SEQUENCE (NCT06696183)
- Testing
- Gilteritinib (GILT), Venetoclax (VEN), Azacitidine (AZA)
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Technische Universität Dresden
Acute Myeloid Leukemia (AML)
Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML
This prospective observational study aims to evaluate the clinical significance of measurable residual disease (MRD) monitoring using digital PCR (dPCR) in patients with acute myeloid leukemia (AML) following allogeneic…
- Trial name
- NCT07500441
- Testing
- Individualized Digital PCR (dPCR) monitoring
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
AML (Acute Myeloid Leukemia)
A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
The goal of this study is to evaluate the safety of CHM-029, an investigational oral medicine, and to evaluate its activity in treating certain types of acute myeloid leukemia (AML) in adults.
- Trial name
- NCT07751991
- Testing
- CHM-029
- Where
- 5 sites in United States, United Kingdom
- Volunteers
- 40 people
- Sponsor
- Charm Therapeutics
Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML
This is a randomized, multi-center, double-blind, placebo-controlled study designed to evaluate the efficacy of crenolanib administered following salvage chemotherapy, consolidation chemotherapy, post bone marrow transplantation…
- Trial name
- NCT03250338
- Testing
- Crenolanib, Cytarabine, Mitoxantrone
- Where
- 62 sites in United States, Canada and 4 more
- Volunteers
- 106 people
- Sponsor
- Arog Pharmaceuticals, Inc.
Ropeginterferon, Alfa-2b
A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in MDS/AML With TP53 Mutations
To find the recommended dose of ropeginterferon alfa-2b in combination with azacitidine in patients with newly diagnosed MDS/AML with TP53 mutations.
- Conditions
- Ropeginterferon, Alfa-2b, Azacitidine, MDS/AML
- Trial name
- NCT07646821
- Testing
- ropeginterferon alfa- 2b, Azacitidine (AZA)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Germline Mutation, Myelodysplastic Syndromes
Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants
Background: Hereditary hematopoietic malignancy (HHM) syndromes are a group of inherited disorders that raises the risk of blood cancers.
- Conditions
- Germline Mutation, Myelodysplastic Syndromes, Acute Myeloid Leukemia
- Trial name
- NCT07019155
- Where
- United States
- Volunteers
- 510 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia With Gene Mutations, Adult Acute Myeloid Leukemia in Remission
Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant
This phase 2 trial studies the side effects and how well midostaurin works in treating older patients with acute myeloid leukemia with change in genetic material post-hematopoietic cell transplantation.
- Trial name
- NCT02723435
- Testing
- Midostaurin
- Sponsor
- Stanford University
DDX41 Gene Mutation
Study of Families With an Hemopathies Predisposition Related to the DDX41 Gene.
This is a multicenter, interventional, historico-prospective cohort pilot study aimed at specifying the phenotype of subjects carrying a constitutional familial DDX41 mutation, with a view to eventually publishing oncogenetic…
- Trial name
- LUCID (NCT06022016)
- Testing
- For each person (index case or related) included in this study:
- Where
- 5 sites in France
- Volunteers
- 910 people, healthy volunteers welcome
- Sponsor
- Institut Claudius Regaud
Leukemia
Studying Biomarkers in Cell Samples From Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01057199
- Testing
- RNA analysis, gene expression analysis, mutation analysis
- Volunteers
- 6 people
- Sponsor
- Children's Oncology Group
Acute Myeloid Leukemia
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
The purpose of the study is to determine whether CEP-701 given in sequence with induction chemotherapy increases the proportion of patients with relapsed acute myeloid leukemia (AML) who achieve a second complete remission (CR).
- Trial name
- NCT00079482
- Testing
- CEP-701, high-dose cytarabine, Mitozantrone, Etoposide, Cytarabine (combination Chemotherapy)
- Where
- 81 sites in United States, Australia and 11 more
- Volunteers
- 224 people
- Sponsor
- Cephalon